Communication

A Traceless Vascular‐Targeting Antibody–Drug Conjugate for Cancer Therapy^†

Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Wolfgang‐Pauli Str. 10, 8093 Zürich (Switzerland)

Search for more papers by this author

Dr. Giulio Casi

Philochem AG, Libernstrasse 3, 8112 Otelfingen (Switzerland)

Search for more papers by this author

Dr. Sabrina Trüssel

Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Wolfgang‐Pauli Str. 10, 8093 Zürich (Switzerland)

Search for more papers by this author

Isabelle Hartmann

Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Wolfgang‐Pauli Str. 10, 8093 Zürich (Switzerland)

Search for more papers by this author

Dr. Kathrin Schwager

Philochem AG, Libernstrasse 3, 8112 Otelfingen (Switzerland)

Search for more papers by this author

Dr. Jörg Scheuermann

Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Wolfgang‐Pauli Str. 10, 8093 Zürich (Switzerland)

Search for more papers by this author

Prof. Dario Neri

Corresponding Author

E-mail address: dario.neri@pharma.ethz.ch

Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Wolfgang‐Pauli Str. 10, 8093 Zürich (Switzerland)

Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Wolfgang‐Pauli Str. 10, 8093 Zürich (Switzerland)Search for more papers by this author

Dr. Gonçalo J. L. Bernardes

Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Wolfgang‐Pauli Str. 10, 8093 Zürich (Switzerland)

Search for more papers by this author

Dr. Giulio Casi

Philochem AG, Libernstrasse 3, 8112 Otelfingen (Switzerland)

Search for more papers by this author

Dr. Sabrina Trüssel

Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Wolfgang‐Pauli Str. 10, 8093 Zürich (Switzerland)

Search for more papers by this author

Isabelle Hartmann

Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Wolfgang‐Pauli Str. 10, 8093 Zürich (Switzerland)

Search for more papers by this author

Dr. Kathrin Schwager

Philochem AG, Libernstrasse 3, 8112 Otelfingen (Switzerland)

Search for more papers by this author

Dr. Jörg Scheuermann

Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Wolfgang‐Pauli Str. 10, 8093 Zürich (Switzerland)

Search for more papers by this author

Prof. Dario Neri

Corresponding Author

E-mail address: dario.neri@pharma.ethz.ch

Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Wolfgang‐Pauli Str. 10, 8093 Zürich (Switzerland)

Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Wolfgang‐Pauli Str. 10, 8093 Zürich (Switzerland)Search for more papers by this author

First published: 15 December 2011

https://doi.org/10.1002/anie.201106527

Citations: 81

^†

G.J.L.B. is an EMBO and Novartis Foundation Research Fellow. We thank Katrin Gutbrodt for her help in histology and immunofluorescence experiments, Dr. Kathrin Zuberbühler and Nadine Pasche for their help during therapy experiments, and Dr. Eveline Traschel for treating tumor‐bearing mice with IgG(F8). Financial contribution from ETH Zürich, Swiss National Science Foundation, SwissBridge/Stammbach Stiftung, Kommission für Technologie und Innovation (KTI) and Philochem AG is gratefully acknowledged.

Abstract

Right on target: A chemically defined vascular‐targeting antibody–drug conjugate (ADC) that offers comprehensive tumor coverage has been developed. When injected intravenously, this ADC potently inhibited tumor growth in a syngeneic immunocompetent model of murine cancer which cannot be cured by conventional cytotoxic agents.